Premium
Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants
Author(s) -
Lentz SR
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.395
Subject(s) - warfarin , dosing , anticoagulant , medicine , edoxaban , intensive care medicine , oral anticoagulant , cyp2c9 , drug , rivaroxaban , pharmacology , atrial fibrillation , cytochrome p450 , metabolism
Despite rapid growth in the use of direct oral anticoagulants (DOACs), warfarin remains a widely prescribed anticoagulant drug. It is likely that the overall use of warfarin will continue to decline, but not completely disappear, as indications for DOACs expand. This changing anticoagulation landscape, along with the likelihood that personalized genomic information will become increasingly available, has several implications for the future of warfarin dosing strategies .